Monika Lukoseviciute

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: MOLECULAR ONCOLOGY. 2026
Dual PI3K/AKT and CDK4/6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model
Lukoseviciute M; Birgersson M; Ceriani P; Wilhelm M; Kostopoulou ON
Article: BIOMEDICINE & PHARMACOTHERAPY. 2024;180:117500
Enhancing targeted therapy by combining PI3K and AKT inhibitors with or without cisplatin or vincristine in medulloblastoma cell lines in vitro
Lukoseviciute M; Need E; Birgersson M; Dalianis T; Kostopoulou ON
Article: BIOMEDICINE & PHARMACOTHERAPY. 2024;177:116993
Combined targeted therapy with PI3K and CDK4/6, or FGFR inhibitors show synergistic effects in a neuroblastoma spheroid culture model
Lukoseviciute M; Need E; Holzhauser S; Dalianis T; Kostopoulou ON
Article: ORAL ONCOLOGY. 2024;151:106749
Human papillomavirus (HPV) load is higher in HPVDNA/p16 positive than in HPVDNA positive/p16 negative oropharyngeal squamous cell carcinoma but does not differ significantly between various subsites or correlate to survival
Zupancic M; Kostopoulou ON; Holzhauser S; Lukoseviciute M; Jylha C; Marklund L; Nasman A; Sivars L; Dalianis T
Article: ONCOLOGY REPORTS. 2023;50(3):166
Efficacy of combined targeted therapy with PI3K and CDK4/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines
Lukoseviciute M; Holzhauser S; Pappa E; Mandal T; Dalianis T; Kostopoulou ON
Article: ONCOLOGY REPORTS. 2023;49(6):125
Combination of PARP and WEE1 inhibitors in vitro: Potential for use in the treatment of SHH medulloblastoma
Lukoseviciute M; Theodosopoulou A; Holzhauser S; Dalianis T; Kostopoulou ON
Article: CANCERS. 2022;15(1):93
Targeted Therapy with PI3K, PARP, and WEE1 Inhibitors and Radiotherapy in HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy while Effects with APR-246 Are Limited
Byskata K; Lukoseviciute M; Tuti F; Zupancic M; Kostopoulou ON; Holzhauser S; Dalianis T
Article: VIRUSES-BASEL. 2022;14(7):1372
Targeted Therapy of HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy between CDK4/6, PI3K and Sometimes FGFR Inhibitors, but Rarely between PARP and WEE1 Inhibitors
Kostopoulou ON; Zupancic M; Pont M; Papin E; Lukoseviciute M; Mikelarena BA; Holzhauser S; Dalianis T
Article: FRONTIERS IN ONCOLOGY. 2021;11:748657
Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines
Lukoseviciute M; Maier H; Poulou-Sidiropoulou E; Rosendahl E; Holzhauser S; Dalianis T; Kostopoulou ON
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2021;58(2):211-225
Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines
Holzhauser S; Lukoseviciute M; Papachristofi C; Vasilopoulou C; Herold N; Wickstrom M; Kostopoulou ON; Dalianis T
Article: ANTICANCER RESEARCH. 2020;40(1):53-66
Targeting Fibroblast Growth Factor Receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) Signaling Pathways in Medulloblastoma Cell Lines
Holzhauser S; Lukoseviciute M; Andonova T; Ursu RG; Dalianis T; Wickstrom M; Kostopoulou ON

Alla övriga publikationer

Doctoral thesis: 2025
Novel strategies of optimal combinations of targeted therapy in medulloblastoma and neuroblastoma
Lukoseviciute M
Review: ANTICANCER RESEARCH. 2023;43(9):3829-3839
New Approaches Towards Targeted Therapy for Childhood Neuroblastoma
Dalianis T; Lukoseviciute M; Holzhauser S; Kostopoulou ON

Anställningar

Postdoktor, Onkologi-Patologi, Karolinska Institutet, 2026-2028
Doktorand, Onkologi-Patologi, Karolinska Institutet, 2022-2026

Examina och utbildning

Medicine Doktorsexamen, Institutionen för onkologi-patologi, Karolinska Institutet, 2025
Medicine Masterexamen, Karolinska Institutet, 2022
Medicine Kandidatexamen, Karolinska Institutet, 2020

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI